Press Releases

<< Back

CHF Solutions Announces the Launch of Pediatric Ultrafiltration Therapy Using the Aquadex SmartFlow System at Children’s Hospital of The King’s Daughters

Jun 4, 2020

EDEN PRAIRIE, Minn., June 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced Children’s Hospital of The King’s Daughters (CHKD) in Norfolk, Virginia has initiated ultrafiltration therapy using the Aquadex SmartFlow™ system.

“Following FDA clearance and the launch of the Aquadex SmartFlow system in the first quarter, we continue to see strong interest from pediatric hospitals,” said John Erb, chairman and CEO of CHF Solutions.  “We are proud to work with the medical team at Children’s Hospital of The King’s Daughters to bring this simple, gentle and smart therapy to its patients suffering from fluid overload.”

“We will use this ultrafiltration therapy to accommodate the needs of children that require fluid removal without the added risk of hemodialysis and to meet the needs of ICU patients with heart disease that don’t respond to diuretics,” said Dr. Irene Restaino, M.D., Medical Director of Nephrology at CHKD.

About Children’s Hospital of The King’s Daughters

CHKD is the only freestanding children’s hospital in Virginia and serves the medical and surgical needs of children throughout greater Hampton Roads, the Eastern Shore of Virginia, and northeastern North Carolina.  The not-for-profit CHKD Health System operates primary care pediatric practices, surgical practices, multi-service health centers, urgent care centers and satellite offices throughout its service region.

About CHF Solutions 

CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation.  The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland.  The company has been listed on the Nasdaq Capital Market since February 2012.

About the Aquadex SmartFlow System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload).  The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.  All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the increased interest in therapy using the Aquadex SmartFlow system with pediatric patients.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.  Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made.  CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


CONTACTS

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

MEDIA:

Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com

chf.jpg

Source: CHF Solutions, Inc.